株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:季節性インフルエンザワクチン - 日本における医薬品の予測と市場分析

PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis

発行 GlobalData 商品コード 258670
出版日 ページ情報 英文 55 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint:季節性インフルエンザワクチン - 日本における医薬品の予測と市場分析 PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis
出版日: 2012年11月30日 ページ情報: 英文 55 Pages
概要

2012年における日本のインフルエンザワクチン市場は、およそ7億200万米ドルとなりました。大手国際企業の参入や、同国政府による予防接種の重要性の国民に対する啓蒙への取り組み、高齢者人口の増加などが今後の成長因子となるでしょう。

当レポートでは、日本の季節性インフルエンザワクチン市場について調査し、市場の概要、競合情勢、主要薬剤の詳細情報とSWOT分析、主要薬剤の売上予測、主要イベントの影響分析、市場影響因子の分析などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状
  • 予後

第4章 疾病管理

  • インフルエンザ予防接種政策
  • 日本
    • ンフルエンザ予防接種の推奨・政策
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合評価
  • 製品プロファイル:主要ブランド

第6章 機会・アンメットニーズ

  • 概要
  • アンメットニーズ
    • 高い患者認識の水準
    • 高齢者・子供(2歳以下)における効能の向上
    • 改善したワクチン副作用のプロファイル
    • より効率的なワクチン製造プロセス
    • よりコスト効果的なワクチン
  • ギャップ分析
  • 機会
    • ウィルス株に対する防御幅の拡大
    • 防御持続期間の増加
    • T細胞の関与

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望薬剤

第8章 市場展望

  • 日本
    • 予測
    • 主なイベント
    • 促進因子・阻害因子

第9章 付録

図表

目次
Product Code: GDHC1017CFR

Summary

GlobalData has released its new Country report, "PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis". Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

The Japanese influenza vaccine market is valued at approximately $702 million in 2012. The projected drivers for growth of the Japanese influenza vaccine market include the entrance of large, multinational firms into the marketplace, a government commitment to educating the populace about the importance of preventative medicine (including vaccination), and growth of the elderly population. GlobalData does not project that intradermal and intranasal vaccines will enter the Japan market during the forecast period, leaving all market dynamics between existing and new intramuscular vaccines.

The Japanese influenza vaccine market differs from its US or European counter parts due the large role that non-commercial entities play in the marketplace. For example, the Chemo-Sero-Therapeutic Research Institute is the market leader. The organization is also referred to as Kaketsuken (abbreviation of its name in Japanese). Kaketsuken's recent completion of a new influenza vaccine plant, which doubled its production capacity, is an embodiment of the resources and commitment to the influenza vaccines that have enabled it to attain its position in the Japanese market.

Scope

  • Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2012 to 2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan seasonal influenza market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012 to 2022 in Japan

Table of contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis

4. Disease Management

  • 4.1. Influenza Vaccination Policy
  • 4.2. Japan
    • 4.2.1. Influenza Vaccination Recommendations and Policies
    • 4.2.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Higher level of patient awareness
    • 6.2.2. Increased efficacy in the elderly and young children (<2 years old)
    • 6.2.3. Improved vaccine side-effect profiles
    • 6.2.4. More efficient vaccine manufacturing process
    • 6.2.5. More cost-effective vaccines
  • 6.3. Gap Analysis
  • 6.4. Opportunities
    • 6.4.1. Expanded breadth of protection against viral strains
    • 6.4.2. Increased duration of protection
    • 6.4.3. T-cell involvement

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising vaccines in clinical development
    • 7.2.1. ASP7374 (UMN-0502)

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Vaccine Coverage
    • 9.4.2. Vaccines Included
    • 9.4.3. Key Launch Dates
    • 9.4.4. Influenza Vaccine Tender System Assumptions
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Vaccine Assumptions
    • 9.4.7. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Authors
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Contact Us
  • 9.10. Disclaimer

List of Tables

  • Table 1: Notable Influenza Pandemics
  • Table 2: Symptoms of Influenza
  • Table 3: Influenza Vaccination Recommendation Committees by Country
  • Table 4: Leading Influenza Vaccines, 2012
  • Table 5: Overall Unmet Needs - Current Level of Attainment
  • Table 6: Clinical Unmet Needs - Gap Analysis, 2012
  • Table 7: Seasonal Influenza Vaccines - Phase Pipeline, 2012
  • Table 8: Product Profile - ASP7374 (UMN-0502)
  • Table 9: ASP7374 (UMN-0502) SWOT Analysis, 2012
  • Table 10: Sales Forecasts ($m) for Influenza Vaccines in Japan, 2012-2022
  • Table 11: Key Events Impacting Sales of Influenza Vaccines in Japan, 2012
  • Table 12: Influenza Vaccine Market - Drivers and Barriers, 2012
  • Table 13: Key Launch Dates
  • Table 14: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Influenza Virus Structure
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Seasonal Influenza, 2012-2022
Back to Top